<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03590262</url>
  </required_header>
  <id_info>
    <org_study_id>723</org_study_id>
    <nct_id>NCT03590262</nct_id>
  </id_info>
  <brief_title>Effect of Metformin as add-on Therapy on Glycemic Control and Other Outcomes in Type 1 Diabetes</brief_title>
  <official_title>Effect of Metformin as add-on Therapy on Glycemic Control and Other Diabetes‑Related Outcomes in Type 1 Diabetic Patients:a Open-label,Self-control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim Evidence of a possible connection between gut microbiota and several physiological
      processes linked to type 1 diabetes is increasing. However, the effect of multistrain
      probiotics in people with type 1 diabetes remains unclear. This study investigated the effect
      of metformin as add-on therapy on glycemic control and other diabetes-related outcomes in
      people with type 1 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design An open-label, add-on, self-control clinical trial. Setting Diabetes clinic of a
      teaching hospital in Shenzhen China Participants A total of 20 participants with type 1
      diabetes, aged 18-60 years, will be recruited and treated with metformin as add-on therapy
      with insulin for 12 weeks.

      Outcomes Primary outcomes were glycemic control related parameters, and secondary outcomes
      were anthropomorphic variables, lipid profile, blood pressure and high-sensitivity C-reactive
      protein. The gut microbiota profile will be analyzed before and after intervention .
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of hemoglobin A1c in percentage</measure>
    <time_frame>3 months</time_frame>
    <description>analyze the change of hemoglobin A1c before and after the treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of weight in kilograms</measure>
    <time_frame>3 months</time_frame>
    <description>analyze the change of weight in kilograms before and after the treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Metformin</condition>
  <arm_group>
    <arm_group_label>metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients take metformin 500mg twice or three times a day as add-on therapy to insulin for 3 months ,using self-control method.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>take the metformin 500mg twice or three times a day</description>
    <arm_group_label>metformin</arm_group_label>
    <other_name>metformin hydrochloride tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        type 1 diabetes patients age 18-60years old 18 Kg/m2≤BMI≤30Kg/m2 ketonuria (-)；

        Exclusion Criteria:

        pregnancy lactation having other severe chronic illnesses taking other anti-diabetic drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fengyi Yuan</last_name>
    <role>Principal Investigator</role>
    <affiliation>associate chief physician</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiuzhen Zhang</last_name>
    <phone>86-13714902238</phone>
    <email>876538754@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ping Xu</last_name>
    <phone>86-13692156916</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuzhen Zhang, MD</last_name>
      <phone>0086-755-22943422</phone>
      <email>876538754@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>July 6, 2018</study_first_submitted>
  <study_first_submitted_qc>July 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2018</study_first_posted>
  <last_update_submitted>July 18, 2018</last_update_submitted>
  <last_update_submitted_qc>July 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

